HOPE Therapeutics, Inc., a wholly-owned subsidiary of NRx Pharmaceuticals, Inc., announced the signing of a binding Letter of Intent to acquire a majority interest in Neurospa TMS Holdings, LLC (Neurospa). Neurospa operates six interventional psychiatry clinics on Florida's Gulf Coast.
Neurospa is a revenue-generating and EBITDA-positive entity, leveraging state-of-the-art interventional psychiatry procedures including Ketamine Infusion Therapy, Transcranial Magnetic Stimulation (TMS), and Spravato. These treatments are augmented by traditional psychiatry and talk therapy to provide comprehensive care.
The acquisition of Neurospa will constitute a key element of HOPE's Florida network, expanding its geographic reach and service offerings. The intended acquisition is subject to the completion of financial audits, execution of definitive agreements, and the satisfaction of standard closing conditions.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.